The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies

Lack of effect of multiple doses of vortioxetine on the pharmacokinetics and pharmacodynamics of aspirin and warfarin

(2015) Grace Chen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Vortioxetine in Adults With Major Depressive Disorder

(2015) Atul R. Mahableshwarkar et al.   JOURNAL OF CLINICAL PSYCHIATRY

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Vortioxetine 10 mg and 20 mg in Adults With Major Depressive Disorder

(2015) Paula L. Jacobsen et al.   JOURNAL OF CLINICAL PSYCHIATRY

Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men

(2015) Sue Wilson et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines

(2015) Anthony Cleare et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction

(2015) Paula L. Jacobsen et al.   Journal of Sexual Medicine

Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data

(2015) Connie Sanchez et al.   PHARMACOLOGY & THERAPEUTICS

A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD

(2015) Atul R. Mahableshwarkar et al.   PSYCHOPHARMACOLOGY

Population Pharmacokinetic Meta-Analysis of Vortioxetine in Healthy Individuals

(2014) Johan Areberg et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder

(2014) Atul R. Mahableshwarkar et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults

(2014) Roger S. McIntyre et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant

(2013) Grace Chen et al.   CLINICAL DRUG INVESTIGATION

A Randomized Trial on the Acute and Steady-State Effects of a New Antidepressant, Vortioxetine (Lu AA21004), on Actual Driving and Cognition

(2013) E L Theunissen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

P.2.b.011 Vortioxetine (Lu AA21004) 15 and 20 mg/day: open-label long-term safety and tolerability in major depressive disorder

(2013) G. Filippov et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder

(2013) Mohammed Y. Alam et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day

(2013) Jean-Philippe Boulenger et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

(2013) L. Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder

(2013) A. R. Mahableshwarkar et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

The Role of Cannabinoids in Chronic Pain Patients Remains Hazy

(2012) B C Chen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder

(2012) David S. Baldwin et al.   CURRENT MEDICAL RESEARCH AND OPINION

A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder

(2012) Atul R. Mahableshwarkar et al.   CURRENT MEDICAL RESEARCH AND OPINION

Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States

(2012) Anthony J. Rothschild et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial

(2012) Leszek Bidzan et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

P.2.c.010 The multimodal antidepressant Lu AA21004: open-label long-term safety and tolerability study in major depressive disorder

(2012) I. Florea et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

(2012) Cornelius Katona et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder

(2012) Rakesh Jain et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A Randomized, Double-Blind, Placebo-Controlled 8-Week Trial of the Efficacy and Tolerability of Multiple Doses of Lu AA21004 in Adults With Major Depressive Disorder

(2012) Neven Henigsberg et al.   JOURNAL OF CLINICAL PSYCHIATRY

A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)

(2011) David S. Baldwin et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

(2011) Enric Alvarez et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder

(2011) Benny Bang-Andersen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pharmacokinetics of Gabapentin in a Novel Gastric-Retentive Extended-Release Formulation: Comparison With an Immediate-Release Formulation and Effect of Dose Escalation and Food

(2010) Cuiping Chen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.

(2009) Raymond W. Lam et al.   JOURNAL OF AFFECTIVE DISORDERS